User profiles for Paolo Fusco

Paolo Fusco

Fellow, “Magna Graecia” University of Catanzaro
Verified email at studenti.unicz.it
Cited by 224

[HTML][HTML] Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility

…, MC Pelle, B Tassone, E Arrighi, G Perri, P Fusco… - Scientific reports, 2020 - nature.com
Since December 2019, coronavirus disease 2019 (COVID-19) pandemic has spread from
China all over the world and many COVID-19 outbreaks have been reported in long-term care …

Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study

…, V Scaglione, C Davoli, P Fusco… - Therapeutic …, 2020 - journals.sagepub.com
The worldwide spread of coronavirus disease 2019 (COVID-19), caused by the new severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the …

[HTML][HTML] Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: a real-life multicenter Italian observational study

…, I Abbate, L Bordi, S Mazzotta, P Fusco… - American Journal of …, 2023 - Elsevier
BACKGROUND Valacyclovir is the only treatment demonstrated to be effective for the
prevention of vertical transmission of cytomegalovirus within a clinical randomized, placebo-…

New advances in management and treatment of multidrug-resistant Klebsiella pneumoniae

A Russo, P Fusco, HL Morrone… - Expert Review of Anti …, 2023 - Taylor & Francis
Introduction The management of multidrug-resistant (MDR) Klebsiella pneumoniae (KP)
represents a major challenge in the field of infectious diseases. It is associated with a high rate …

Prevalence of antibiotic resistance over time in a third-level University Hospital

…, R Lionello, V La Gamba, P Fusco… - Microbial Drug …, 2022 - liebertpub.com
This study evaluated the spread and possible changes in resistance patterns of ESKAPE
bacteria to first-choice antibiotics from 2015 to 2019 at a third-level university hospital after …

[HTML][HTML] Touching base with some Mediterranean diseases of interest from paradigmatic cases at the “Magna Graecia” university unit of infectious diseases: a …

…, S Rotundo, G Bruno, G Marino, HL Morrone, P Fusco… - Diagnostics, 2023 - mdpi.com
Among infectious diseases, zoonoses are increasing in importance worldwide, especially in
the Mediterranean region. We report herein some clinical cases from a third-level hospital in …

[HTML][HTML] Weight of clinical and social determinants of metabolic syndrome in people living with HIV

M Mazzitelli, P Fusco, M Brogna, A Vallone… - Viruses, 2022 - mdpi.com
Background. Comorbidities in people living with HIV (PLWH) represent a major clinical
challenge today, and metabolic syndrome (MTBS) is one of the most important. Objective. Our …

[HTML][HTML] Efficacy, convenience, safety and durability of DTG-based antiretroviral therapies: evidence from a prospective study by the Italian MaSTER cohort

P Fusco, P Nasta, E Quiros-Roldan, A Tondinelli… - Viruses, 2023 - mdpi.com
Background: Dolutegravir (DTG) is recommended by international guidelines as a main
component of an optimal initial regimen of cART (combination antiretroviral treatment) in people …

[HTML][HTML] Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort

…, V Borghi, F Lagi, A Latini, G d'Ettorre, L Oreni, P Fusco… - Viruses, 2022 - mdpi.com
Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral
therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We …

[HTML][HTML] The spike-specific TCRβ repertoire shows distinct features in unvaccinated or vaccinated patients with SARS-CoV-2 infection

…, R Gallo, C Giordano, F Serapide, P Fusco… - Journal of Translational …, 2024 - Springer
Background The evolving variants of SARS-CoV-2 may escape immunity from prior infections
or vaccinations. It’s vital to understand how immunity adapts to these changes. Both …